焦點新股！賽生藥業自家製「日達仙」治療SARS、新冠肺炎！接棒諾輝健康續領IPO狂熱！【uSMART投資熱話20210218】
Author: uSMART Securities
生物製藥公司賽生藥業將在港上市，公司自有產品「日達仙」在治療SARS及COVID-19方面，獲得醫生、患者及國家的認可，非常厲害！賽生仲有同國藥、輝瑞、百特有合作，令人期待！隨著諾輝健康(6606.HK)上市，釋放大量資金回籠，賽生藥業相信可接棒繼續這股IPO狂熱！
Share:
Free Registration
+852
Login by Password
*Mandatory
Registration indicates you agree with our registration agreement and the use of personal data in direct marketing prescribed in registration agreement. For registered users, you can edit the relevant setting on the use of personal data via Personal Centre section, if necessary.
